CD8A and cancer: Our current study advances the understanding of how PIKfyve mediates immune evasion in cancer, whereby PIKfyve downregulates surface MHC-I, a complex which is crucial for CD8+ T cell recognition and CD8+ T cell–dependent immunotherapies.